Stockreport

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Protara Therapeutics, Inc.  (TARA) 
PDF TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive/Experienced patients in ongoing NMIBC programTARA-002 demonstrated a complete r [Read more]